Thursday, OCTOBER 29 | 2:00 PM ET

Evofem Biosciences, Inc.

Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi™ (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is also advancing EVO100 into a Phase 3 clinical trial for the prevention of urogenital transmission of both Chlamydia trachomatis and Neisseria gonorrhoeae in women.

Featured Key Opinion Leader

Patty Cason, RN, MS, FNP-BC
President, Envision SRH

Patty Cason is a family nurse practitioner, trainer, and educator with a specialty in sexual and reproductive health. She has practiced for 38 years in a wide variety of clinical and academic settings and is a contracted consultant to training agencies, non-profits, and state departments of health across the United States. Patty serves on the National Medical Committee for Planned Parenthood Federation of America. She is also a member of the ASCCP Board of directors and is a member of the Communications Workgroup that developed the 2019 Risk-Based Management Consensus Guidelines. Patty developed the “PATH” framework for person-centered reproductive goals and contraception counseling. She is an editor of the 21st edition of Contraceptive Technology for which she wrote a seminal chapter on reproductive goals and contraception counseling.  Other publications include research and opinion pieces in peer reviewed journals, nationally utilized on-line learning courses, instructional videos, textbook chapters, clinical protocols, job aids, and manuals.

Management

Saundra Pelletier
Chief Executive Officer

Saundra Pelletier has served as Chief Executive Officer, President and Executive Director of Evofem Biosciences since February 2015. Ms. Pelletier has been responsible for the company’s growth and evolution, and she led Evofem’s transition to the public market in January 2018 (NASDAQ: EVFM).

 

Ms. Pelletier has assembled an impressive team of seasoned pharmaceutical professionals that have a deep understanding of the women’s healthcare market and what women want, and she attracted new investor capital. She has also led multiple equity financing rounds which have raised in excess of $400 million.

 

In her more than 25 years of experience in the pharmaceutical industry, Ms. Pelletier has launched pharmaceutical brands worldwide and expanded indications on female healthcare brands in multiple countries. Her experience includes a comprehensive range of women’s healthcare products, cardiovascular, pain management, sleep therapies and medical devices. She has had oversight and accountability for Sales, Marketing, Operations, Medical Affairs, Regulatory Affairs, Manufacturing, Customer Service, Business Development and Strategic Partnerships.

 

Previously, Ms. Pelletier served as Vice President, Pharmaceuticals at Women First Healthcare, where she raised $40 million in capital. Earlier in her career, Ms. Pelletier served as Corporate Vice President and Global Franchise Leader for G.D. Searle, where she managed a $250 million business unit, managed worldwide partnerships, negotiated cost saving licensing agreements, assessed country infrastructures, developed commercialization plans and hired full scale teams, including contract sales forces.

 

Ms. Pelletier currently serves on the board of directors for TRACON Pharmaceuticals, Inc. She is also a published author, coveted keynote speaker and moderator at key healthcare and political conferences worldwide.

 

She has appeared at the Harvard School of Public Health, the Davos World Economic Forum, the Clinton Global Initiative, the MAKERS Conference, Women Deliver, the University of Virginia’s Darden School of Business, the University of Oregon’s Lundquist School of Business and the University of California, San Diego.

 

She is a trained Climate Reality Advocate and hosted a roundtable session at the International Conference on Climate Change, held in Reykjavik, Iceland. Ms. Pelletier has been profiled by The New York Times, Inc. Magazine, Cosmopolitan, Bustle, CNN, Glamour, Marie Claire, and Vogue. She was named as a New Champion for Reproductive Health by the United Nations Foundation, was awarded the Athena San Diego’s Pinnacle Award for Life Sciences, which recognizes an extraordinary leader in the application of technical advances in life sciences to develop commercial products, and was awarded San Diego Business Journal's 2019 Business Woman of the Year Award.

Kelly Culwell, MD
Chief Medical Officer, Evofem Biosciences, Inc.

Dr. Kelly Culwell is an Obstetrician/Gynecologist with over 16 years specializing in women’s health and contraceptive research. She has served as Evofem Biosciences' Chief Medical Officer since April 2015.
 

Prior to joining Evofem Biosciences, Dr. Culwell was the Medical Director of Planned Parenthood of the Pacific Southwest and maintained an academic clinical practice as the Director of Family Planning and Associate Clinical Professor at the University of California, Davis. She previously served as a Medical Officer with the World Health Organization, where she developed global guidelines for clinical practice. Dr. Culwell is widely published in peer-reviewed journals.
 

Dr. Culwell received a Bachelor of Science from California Lutheran University, a Medical Doctorate from the University of California, Davis, and a Masters of Public Health from Northwestern University. Dr. Culwell completed her post-graduate training in Obstetrics and Gynecology at the University of California San Diego and her Family Planning Fellowship at Northwestern University. She maintains appointments as Volunteer Assistant Clinical Professor in the Departments of Obstetrics and Gynecology at the University of California, Davis, and San Diego campuses. Dr. Culwell is qualified as a Diplomat from the American Board of Obstetrics and Gynecology. Dr. Culwell also serves as a Director of WCG Cares, a 501c3 working in sexual and reproductive health globally.

JTC_noText.png
Moderated by:
Jenene Thomas, CEO, JTC Team
© 2020 Virtual Investor. All rights reserved.
HeaderImage_10.22.20.png